Related Experiment Video
Updated: Apr 15, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Vitamin D status and response to supplementation in very preterm infants: A prospective cohort study
Suphawe Wasuanankun1, Prattana Rattanachamnongk2, Buranee Yangthara3
1Department of Pediatrics, Golden Jubilee Medical Center, Mahidol University, Nakhon Pathom, Thailand.
Insights
Vitamin D deficiency is common in very preterm infants. Daily intake under 400 IU/kg typically normalizes vitamin D levels by 8 weeks, reducing risks associated with deficiency and excess.
Area of Science:
- Neonatology
- Pediatric Endocrinology
- Nutritional Science
Background:
- Very preterm infants face high risks of vitamin D deficiency (VDD), contributing to metabolic bone disease (MBD) and other complications.
- Optimal vitamin D dosing for these infants remains unclear despite existing guidelines.
- This study investigated VDD incidence and 25-hydroxyvitamin D [25(OH)D] responses to different vitamin D intakes in early life.
Purpose of the Study:
- To determine the incidence of vitamin D deficiency (VDD) in very preterm infants.
- To evaluate the impact of varying vitamin D intakes on serum 25-hydroxyvitamin D [25(OH)D] levels within the first 8 weeks of life.
- To assess the safety and efficacy of different vitamin D supplementation regimens.
Main Methods:
- A prospective cohort study of infants born before 32 weeks' gestation or with birth weight under 1500g.
- Infants were grouped by total vitamin D intake (parenteral and enteral) during weeks 0-4: <400, 400-700, or >700 IU/kg/day.
- Serum 25(OH)D levels were measured at birth, 4 weeks, and 8 weeks; VDD was defined as <20 ng/mL and vitamin D excess (VDE) as >100 ng/mL.
Main Results:
- High VDD prevalence at birth (94.3%). At 4 weeks, VDD persisted in 17.8% (<400 IU/kg/day) and 6.5% (400-700 IU/kg/day), with minimal VDE.
- By 8 weeks, 90.1% achieved normal 25(OH)D with <400 IU/kg/day, compared to 77.4% with 400-700 IU/kg/day.
- Higher intakes (400-700 IU/kg/day) led to increased VDE (22.6%) by 8 weeks; MBD occurred in only one infant.
Conclusions:
- VDD is nearly universal at birth in very preterm infants.
- A daily intake of less than 400 IU/kg effectively normalized vitamin D status by 8 weeks, minimizing risks of both deficiency and excess.
- Higher vitamin D doses did not offer additional benefits and increased the risk of vitamin D excess.
Background:
Very preterm infants are at high risk of vitamin D deficiency (VDD), which contributes to metabolic bone disease (MBD) and other morbidities. Despite guidelines, optimal dosing remains uncertain. We determined VDD incidence and evaluated 25-hydroxyvitamin D [25(OH)D] responses to varying vitamin D intakes during the first 8 weeks of life.
Methods:
This prospective cohort enrolled infants born at <32 weeks' gestation or birth weight <1500 g. Vitamin D supplementation followed institutional policy. Infants were categorized by total intake (parenteral plus enteral) during weeks 0-4: <400, 400-700, or >700 IU/kg/day. Serum 25(OH)D was measured at birth, 4, and 8 weeks. Biochemical markers and MBD screening were performed. VDD was defined as 25(OH)D < 20 ng/mL and excess (VDE) as >100 ng/mL.
Results:
Among 126 infants (gestational age 30 [27, 31] weeks; birth weight 1230 [950, 1570] g), 94.3% had VDD at birth. At 4 weeks, VDD persisted in 17.8% receiving <400 IU/kg/day and 6.5% receiving 400-700 IU/kg/day; vitamin D excess (VDE) occurred in 3.3% and 3.2%, respectively. At 8 weeks, normal 25(OH)D was achieved in 90.1% receiving <400 IU/kg/day and 77.4% receiving 400-700 IU/kg/day, while VDE increased to 8.6% and 22.6%, respectively. Biochemical markers remained normal; only one infant developed MBD.
Conclusions:
VDD is highly prevalent at birth in very preterm infants. Daily intake <400 IU/kg generally normalizes vitamin D status by 8 weeks while minimizing risk of excessive vitamin D. Higher doses may provide no additional benefit and increase risk of exceeding 25(OH)D levels.
Clinical Trial Registration:
Thai Clinical Trials Registry. Registration number TCTR20230725007. Web link: http://www.thaiclinicaltrials.org/show/TCTR20230725007 .
Related Concept Videos
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Factors Affecting Drug Response: Overview